Denali Therapeutics Stock Market Value
| DNLI Stock | USD 13.61 0.02 0.15% |
| Symbol | Denali |
Denali Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Denali Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Denali Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Denali Therapeutics.
| 06/05/2024 |
| 07/30/2025 |
If you would invest 0.00 in Denali Therapeutics on June 5, 2024 and sell it all today you would earn a total of 0.00 from holding Denali Therapeutics or generate 0.0% return on investment in Denali Therapeutics over 420 days. Denali Therapeutics is related to or competes with Alector, Legend Biotech, Ascendis Pharma, Cytokinetics, Edgewise Therapeutics, Apellis Pharmaceuticals, and Arvinas. Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerati... More
Denali Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Denali Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Denali Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.1) | |||
| Maximum Drawdown | 16.27 | |||
| Value At Risk | (4.20) | |||
| Potential Upside | 4.94 |
Denali Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Denali Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Denali Therapeutics' standard deviation. In reality, there are many statistical measures that can use Denali Therapeutics historical prices to predict the future Denali Therapeutics' volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.45) | |||
| Total Risk Alpha | (0.80) | |||
| Treynor Ratio | (0.08) |
Denali Therapeutics Backtested Returns
Denali Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0678, which denotes the company had a -0.0678 % return per unit of risk over the last 3 months. Denali Therapeutics exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Denali Therapeutics' Mean Deviation of 2.37, variance of 10.11, and Standard Deviation of 3.18 to check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.88, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Denali Therapeutics will likely underperform. At this point, Denali Therapeutics has a negative expected return of -0.22%. Please make sure to confirm Denali Therapeutics' accumulation distribution, and the relationship between the value at risk and day typical price , to decide if Denali Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.52 |
Good reverse predictability
Denali Therapeutics has good reverse predictability. Overlapping area represents the amount of predictability between Denali Therapeutics time series from 5th of June 2024 to 1st of January 2025 and 1st of January 2025 to 30th of July 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Denali Therapeutics price movement. The serial correlation of -0.52 indicates that about 52.0% of current Denali Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.52 | |
| Spearman Rank Test | -0.32 | |
| Residual Average | 0.0 | |
| Price Variance | 11.46 |
Denali Therapeutics lagged returns against current returns
Autocorrelation, which is Denali Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Denali Therapeutics' stock expected returns. We can calculate the autocorrelation of Denali Therapeutics returns to help us make a trade decision. For example, suppose you find that Denali Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Denali Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Denali Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Denali Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Denali Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Denali Therapeutics Lagged Returns
When evaluating Denali Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Denali Therapeutics stock have on its future price. Denali Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Denali Therapeutics autocorrelation shows the relationship between Denali Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Denali Therapeutics.
Regressed Prices |
| Timeline |
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out Denali Therapeutics Correlation, Denali Therapeutics Volatility and Denali Therapeutics Alpha and Beta module to complement your research on Denali Therapeutics. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Denali Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.